Rheumatoid Factor (RF)
Immunity0 parametersReport in 4HrsAt Home
No Fasting Required
Details
Rheumatoid factor test used in diagnosis of rheumatoid arthritis and other autoimmune conditions.
₹299₹495
40% OFF
FREE:AI Insights
Rheumatoid Factor (RF) - Comprehensive Medical Test Guide
- Why is it done?
- Test measures antibodies (specifically IgM, IgG, or IgA) produced by the immune system that attack the body's own tissues, particularly affecting joints and connective tissue
- Primary indication: Diagnose or confirm rheumatoid arthritis (RA) when joint pain, swelling, and stiffness are present
- Evaluate other autoimmune conditions such as systemic lupus erythematosus (SLE), Sjögren's syndrome, and mixed connective tissue disease
- Assess disease activity and severity in patients already diagnosed with RA
- Monitor treatment response and prognosis in autoimmune disease management
- Typical timing: Performed during initial diagnostic workup when symptoms suggest autoimmune disease, or periodically during disease monitoring
- Normal Range
- Normal/Negative Result: Less than 14 IU/mL (International Units per milliliter) or negative on qualitative testing
- Borderline/Weakly Positive: 14-20 IU/mL - may warrant repeat testing or additional evaluation
- Positive Result: Greater than 20 IU/mL - indicates presence of rheumatoid factor antibodies
- Highly Positive: Greater than 60 IU/mL - suggests higher likelihood of RA or other autoimmune disease
- Units of measurement: IU/mL (International Units per milliliter) or may be reported as positive/negative or as a titer
- Note: Reference ranges may vary slightly between laboratories; consult your specific lab's reference interval
- Normal result indicates absence of detectable rheumatoid factor, suggesting lower likelihood of RA; however, seronegative RA exists in 20-30% of patients
- Interpretation
- Positive RF Result (>20 IU/mL): Suggests autoimmune activity; when combined with clinical symptoms (joint pain, swelling, morning stiffness), strongly supports RA diagnosis
- Negative RF Result (<14 IU/mL): Does not exclude RA diagnosis; seronegative RA occurs in approximately 20-30% of RA patients; further testing with anti-CCP antibodies recommended
- High Titers (>60 IU/mL): Associated with more severe disease, increased risk of extra-articular manifestations (nodules, vasculitis), and worse prognosis
- Borderline Results (14-20 IU/mL): Warrant repeat testing in 4-6 weeks; trending upward increases diagnostic likelihood
- Factors affecting results:
- Age: RF positivity increases with age; may be positive in 5-10% of healthy elderly individuals
- Gender: More common in women; female-to-male ratio approximately 2.5:1 for RA
- Infections: Certain infections (hepatitis C, tuberculosis, EBV) can elevate RF transiently
- Disease activity: RF levels may fluctuate with disease activity in established RA; poor correlation with symptom severity
- Early disease: RF may not appear until several months after symptom onset
- Clinical significance:
- RF-positive patients have worse long-term outcomes compared to RF-negative patients
- Used in combination with anti-CCP antibodies for improved diagnostic accuracy (RF+/anti-CCP+ has highest specificity)
- Helps stratify risk for severe disease and need for aggressive treatment
- Associated Organs
- Primary organ systems involved:
- Musculoskeletal system: Primarily affects synovial joints; inflammatory cascade leads to cartilage and bone destruction
- Immune system: B and T lymphocyte dysfunction; immune complex formation and deposition
- Connective tissue: Systemic inflammation affecting multiple tissue types
- Conditions commonly associated with abnormal RF results:
- Rheumatoid Arthritis (RA): Most common autoimmune condition associated with elevated RF; positive in 70-80% of RA patients
- Systemic Lupus Erythematosus (SLE): Positive RF in 40-60% of SLE patients; indicates more severe disease
- Sjögren's Syndrome: Positive in 50-70% of patients with primary Sjögren's
- Mixed Connective Tissue Disease (MCTD): Frequently RF-positive
- Cryoglobulinemia: Often RF-positive, particularly associated with hepatitis C
- Chronic infections: Tuberculosis, hepatitis C, endocarditis may cause transient RF elevation
- Malignancies: Lymphoma and other cancers occasionally associated with RF positivity
- Extra-articular complications (in RF-positive RA):
- Rheumatoid nodules: Subcutaneous nodules over pressure points (elbows, fingers)
- Pulmonary involvement: Interstitial lung disease, pleural effusion, increased infection risk
- Cardiovascular disease: Increased risk of atherosclerosis, myocardial infarction, pericarditis
- Ocular manifestations: Scleritis, episcleritis, keratitis
- Vasculitis: Systemic vasculitis affecting medium and small vessels
- Felty syndrome: Splenomegaly, leukopenia, thrombocytopenia in RF+ RA patients
- Follow-up Tests
- Recommended additional tests based on RF results:
- Anti-CCP antibodies (anti-cyclic citrullinated peptide): Increased specificity for RA; positive in 65-75% of RA patients; more specific than RF alone; helps diagnose seronegative RA
- Antinuclear antibody (ANA): Screen for systemic autoimmune diseases like SLE and Sjögren's when RF positive
- Erythrocyte sedimentation rate (ESR): Marker of systemic inflammation; correlates with disease activity
- C-reactive protein (CRP): Acute phase reactant; better correlation with clinical activity than ESR in some patients
- Complete blood count (CBC): Assess for anemia, leukopenia, thrombocytopenia; check for Felty syndrome
- Comprehensive metabolic panel: Baseline assessment before starting immunosuppressive therapy
- Liver function tests: Important before initiating DMARDs (disease-modifying antirheumatic drugs)
- Anti-tissue transglutaminase (anti-tTG): Screen for celiac disease (associated with increased RA risk)
- Imaging studies: X-rays of affected joints to assess for structural damage; MRI for early erosive changes
- Monitoring frequency:
- Initial diagnosis: RF testing combined with clinical assessment and imaging; repeat if borderline
- Ongoing disease monitoring: Typically every 3-6 months initially; frequency may decrease with disease remission
- Treatment response assessment: RF levels correlate variably with clinical response; ESR and CRP more reliable for short-term monitoring
- During remission: May monitor annually or less frequently if clinically stable
- Complementary tests for differential diagnosis:
- Anti-double stranded DNA (anti-dsDNA): Specific for SLE when RF positive
- Anti-Ro/SSA and Anti-La/SSB: Differentiates Sjögren's syndrome from other autoimmune diseases
- Anti-mitochondrial antibodies (AMA): Screen for primary biliary cholangitis when RF positive
- Hepatitis C antibody: If RF positive and risk factors present, screen for hepatitis C-associated cryoglobulinemia
- Fasting Required?
- Fasting requirement: NO - Fasting is not required for the rheumatoid factor test
- The RF test measures antibodies in serum and is not affected by food or fluid intake
- Patients may eat and drink normally before the blood draw
- Medications:
- No specific medications need to be discontinued for RF testing
- Continue all current medications including DMARDs, corticosteroids, and biologics as prescribed
- Immunosuppressive medications may affect RF levels but should not be discontinued without physician approval
- Patient preparation requirements:
- Arrive well-hydrated (improves venipuncture success)
- Wear loose-fitting sleeves to facilitate blood draw from the arm
- Inform phlebotomist of any history of difficult venipuncture or bleeding disorders
- No special positioning required; can be drawn while seated or lying down
- Specimen collection: 3-5 mL of serum in standard SST (serum separator tube) or gold-top tube
- Results typically available within 24-48 hours
- No restrictions on activity after blood draw; normal daily activities can be resumed immediately
How our test process works!
